How big is Embecta Corp.?

As of Jun 18, Embecta Corp. has a market capitalization of 575.07 million and reported net sales of 1,079.50 million with a net profit of 52.80 million over the last four quarters. As of Sep 24, shareholder's funds were -738.30 million, and total assets amounted to 1,285.30 million.

As of Jun 18, Embecta Corp. has a market capitalization of 575.07 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 1,079.50 million, while the sum of consolidated net profit for the same period is 52.80 million.<BR><BR>As of Sep 24, the reporting period shows shareholder's funds at -738.30 million and total assets amounting to 1,285.30 million.

What does Embecta Corp. do?

Embecta Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $259 million and a net profit of $24 million. It has a market cap of $575.07 million, a P/E ratio of 6.00, and a dividend yield of 3.03%.

Overview:<BR>Embecta Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 259 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 24 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 575.07 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 6.00 <BR>Dividend Yield: 3.03% <BR>Debt Equity: -1.79 <BR>Return on Equity: -999,999.00% <BR>Price to Book: -0.78 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Embecta Corp.?

Is Embecta Corp. overvalued or undervalued?

As of May 13, 2022, Embecta Corp. is considered undervalued with a low P/E ratio of 6 and a high ROCE of 38.19%, despite its stock underperforming the S&P 500 by -52.45% year-to-date, indicating a shift to a risky valuation grade.

As of 13 May 2022, the valuation grade for Embecta Corp. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company is currently considered undervalued, particularly given its low P/E ratio of 6, a PEG ratio of 0.28, and an EV to EBITDA of 7.04. These ratios suggest that the stock may be trading below its intrinsic value compared to its earnings potential.<BR><BR>In comparison to peers, Embecta Corp. has a significantly lower P/E ratio than LeMaitre Vascular, Inc., which stands at 43.25, and MiMedx Group, Inc., at 21.59. While the industry appears to be performing better, Embecta's high ROCE of 38.19% indicates strong capital efficiency despite its negative book value. Notably, the company's stock has underperformed against the S&P 500, with a year-to-date return of -52.45%, which further emphasizes its current undervaluation in the market.

Is Embecta Corp. technically bullish or bearish?

As of September 26, 2025, Embecta Corp. shows a neutral trend with mixed signals, including a mildly bearish daily moving average and a year-to-date return of -32.69%, significantly underperforming the S&P 500's 12.96%.

As of 26 September 2025, the technical trend for Embecta Corp. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The RSI shows no signal on both weekly and monthly time frames, and the Bollinger Bands reflect a mildly bullish weekly stance but sideways monthly. Dow Theory presents a mildly bearish weekly view and a mildly bullish monthly perspective. <BR><BR>In terms of performance, Embecta Corp. has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -32.69% versus the S&P 500's 12.96%, and a 1-year return of -1.84% compared to 15.64% for the index.